Quote this publication Share Print

XOFIGO (radium), radioisotope

ONCOLOGY - Update
Opinions on drugs - Posted on Mar 29 2017

Reason for request

Re-assessment of the actual benefit and of the improvement in actual benefit

Minor clinical added value relative to placebo in the treatment of castration-resistant prostate cancer, with symptomatic bone metastases

 

  • XOFIGO has had Marketing Authorisation since 2013 as a monotherapy in the treatment of castration-resistant prostate cancer, with symptomatic bone metastases and no known visceral metastases.
  • The benefit of radium dichloride treatment was established relative to placebo in patients with castration-resistant prostate cancer with symptomatic bone metastases. No new optimal-level study is available since the previous assessment.
  • In the absence of data, its role in the chronological sequence compared with abiraterone acetate or enzalutamide in patients presenting only bone metastases is unclear.

 

 


Improvement in actual benefit

IV (mineur)

-


Therapeutic use

-

Contact Us

Évaluation des médicaments